Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

2023265 citationsJournal Articlehybrid Open Access

Authors

T-DXd demonstrated clinically meaningful responses at both doses. Safety profile was acceptable and generally manageable, favoring T-DXd 5.4 mg/kg.

Good health and well-being

Published in: Journal of Clinical Oncology

Volume 41, Issue 31, pp. 4852-4863

Field-Weighted Citation Impact: 60.27